Phelps Charles E, Madhavan Guruprasad, Gellin Bruce
University of Rochester, Rochester, NY, United States.
The National Academies of Sciences, Engineering, and Medicine, Washington, DC, United States.
Vaccine. 2017 Jan 20;35 Suppl 1:A50-A56. doi: 10.1016/j.vaccine.2016.09.072. Epub 2016 Dec 22.
We review a sequence of strategic planning efforts over time in the United States, all involving processes to prioritize new vaccine candidates. The Institute of Medicine of the National Academies of Sciences, Engineering, and Medicine has been involved in three priority setting processes, each using different metrics and methodologies: infant mortality equivalents (1985-1986), cost-effectiveness (2000), and more recently, the implementation of a software system based on a broader multi-criteria systems approach that can include either of the earlier metrics among other various considerations (2015). The systems approach offers users the flexibility to select, combine, rank, weigh and evaluate different attributes representing their perspectives, assumptions, and particular needs. This approach also overcomes concerns relating to the previous single-metric ranking approaches that yielded lists that, once published, were static, and could not readily accommodate new information about emerging pathogens, new scientific advances, or changes in the costs and performance features of interventions. We discuss the rationale and reasoning behind the design of this multi-criteria decision support approach, stakeholder feedback about the tool, and highlight the potential advantages from using this expanded approach to better inform and support vaccine policies.
我们回顾了美国一段时间内一系列战略规划工作,所有这些工作都涉及对新疫苗候选品种进行优先排序的过程。美国国家科学院、工程院和医学院的医学研究所参与了三个优先排序过程,每个过程使用不同的指标和方法:婴儿死亡率当量(1985 - 1986年)、成本效益(2000年),以及最近基于更广泛的多标准系统方法实施的一个软件系统,该方法在其他各种考虑因素中可以纳入早期的任何一个指标(2015年)。该系统方法为用户提供了灵活性,使其能够选择、组合、排序、权衡和评估代表其观点、假设和特定需求的不同属性。这种方法还克服了与以前单一指标排名方法相关的问题,以前的方法产生的列表一旦公布就是固定的,无法轻易纳入有关新出现病原体的新信息、新的科学进展,或干预措施成本及性能特征的变化。我们讨论了这种多标准决策支持方法设计背后的基本原理和推理、利益相关者对该工具的反馈,并强调了使用这种扩展方法为疫苗政策提供更好信息和支持的潜在优势。